Mak, Elijah
Reid, Robert I.
Przybelski, Scott A.
Lesnick, Timothy G.
Schwarz, Christopher G. http://orcid.org/0000-0002-1466-8357
Senjem, Matthew L. http://orcid.org/0000-0001-9308-9275
Raghavan, Sheelakumari
Vemuri, Prashanthi
Jack, Clifford R. Jr http://orcid.org/0000-0001-7916-622X
Min, Hoon Ki
Jain, Manoj K.
Miyagawa, Toji
Forsberg, Leah K.
Fields, Julie A.
Savica, Rodolfo
Graff-Radford, Jonathan
Jones, David T.
Botha, Hugo
St. Louis, Erik K.
Knopman, David S.
Ramanan, Vijay K.
Dickson, Dennis W. http://orcid.org/0000-0001-7189-7917
Graff-Radford, Neill R.
Ferman, Tanis J.
Petersen, Ronald C.
Lowe, Val J.
Boeve, Bradley F. http://orcid.org/0000-0002-4153-8187
O’Brien, John T.
Kantarci, Kejal http://orcid.org/0000-0002-8001-2081
Article History
Received: 19 July 2023
Accepted: 13 March 2024
First Online: 3 April 2024
Competing interests
: E.M., S.A.P., and T.G.L. report no disclosures relevant to the manuscript. C.G.S. receives research support from the NIH. J. G.-R. serves on the editorial board for Neurology and receives research support from NIH. M.L.S. owns or has owned stock in medical-related companies, unrelated to the current work, within the past 36 months: Align Technology, Inc., Inovio Pharmaceuticals, Inc., Mesa Laboratories, Inc., Johnson and Johnson, LHC Group, Inc., Natus Medical Inc., and Varex Imaging Corporation. J.A. Fields reports no disclosures relevant to the manuscript. D.S.K. serves on a Data Safety Monitoring Board for the DIAN study, has served on a Data Safety Monitoring Board for a tau therapeutic for Biogen but received no personal compensation, is a site investigator in Biogen aducanumab trials, is an investigator in clinical trials sponsored by Lilly Pharmaceuticals and the University of Southern California, serves as a consultant for Samus Therapeutics, Roche, Magellan Health and Alzeca Biosciences but receives no personal compensation, and receives research support from the NIH. D.T. Jones reports no disclosures relevant to the manuscript. R. Savica reports no disclosures relevant to the manuscript. V.K. Ramanan receives research funding from the NIH and the Mangurian Foundation for Lewy Body disease research and has provided educational content for Medscape unrelated to this work. T.J.F. receives funding from the Mangurian Foundation for Lewy body research and NIH. N.R.G.-R. reports no disclosures relevant to the manuscript. V.J.L. serves as a consultant for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). C.R.J. has consulted for Lily and serves on an independent data monitoring board for Roche and as a speaker for Eisai, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic. R.C.P. serves as a consultant for Roche, Inc., Merck, Inc., Biogen, Inc., Eisai, Inc., Genentech, Inc., and Nestle, Inc., served on a DSMB for Genentech, receives royalties from Oxford University Press and UpToDate, and receives NIH funding. B.F.B. has served as an investigator for clinical trials sponsored by Biogen and Alector. He receives royalties from the publication of a book entitled Behavioral Neurology of Dementia (Cambridge Medicine, 2017). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the Ted Turner and Family Foundation LBD Functional Genomics Program. E.K.L. has no disclosures related to this work. He has served as a Co-Investigator on K.K. research grant (DLB U01) and as a NAPS co-investigator. J.T.O. has no conflicts related to this study; unrelated to this work he has received honoraria for work as DSMB chair or member for TauRx, Axon, Eisai, has acted as a consultant for Roche, and has received research support from Alliance Medical and Merck. K.K. consults for Biogen, receives research support from Avid Radiopharmaceuticals and Eli Lilly, and receives funding from NIH and Alzheimer’s Drug Discovery Foundation.